As the COVID-19 pandemic continues to impact patients worldwide, America’s biopharmaceutical research companies are working around the clock with stakeholders across the research and development (R&D) ecosystem to advance vaccine candidates that will help prevent infection and stop the spread of the virus. In a matter of months, incredible progress has been made. The private sector has moved more than two dozen unique vaccines from initial R&D into preclinical testing and clinical trials.